(0.47%) 5 070.00 points
(0.32%) 38 192 points
(0.58%) 17 539 points
(0.52%) $79.41
(1.66%) $1.964
(0.51%) $2 322.80
(0.16%) $26.79
(1.43%) $968.60
(0.02%) $0.933
(0.19%) $11.05
(-0.02%) $0.798
(-0.98%) $92.35
3.48% HKD 2.38
Live Chart Being Loaded With Signals
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 119 000 |
Średni wolumen | 124 192 |
Kapitalizacja rynkowa | 1.35B |
EPS | HKD0 ( 2023-08-16 ) |
Następna data zysków | ( HKD0 ) 2024-05-28 |
Last Dividend | HKD0.0450 ( 2023-08-29 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 5.06 |
ATR14 | HKD0.0100 (0.42%) |
Essex Bio-Technology Ltd Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Essex Bio-Technology Ltd Finanse
Annual | 2023 |
Przychody: | HKD1.71B |
Zysk brutto: | HKD1.54B (90.20 %) |
EPS: | HKD0.480 |
FY | 2023 |
Przychody: | HKD1.71B |
Zysk brutto: | HKD1.54B (90.20 %) |
EPS: | HKD0.480 |
FY | 2022 |
Przychody: | HKD1.32B |
Zysk brutto: | HKD1.19B (90.26 %) |
EPS: | HKD0.390 |
FY | 2021 |
Przychody: | HKD1.64B |
Zysk brutto: | HKD1.40B (85.23 %) |
EPS: | HKD0.600 |
Financial Reports:
No articles found.
Essex Bio-Technology Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0400 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0250 (N/A) |
HKD0.0450 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0100 | 2009-04-30 |
Last Dividend | HKD0.0450 | 2023-08-29 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 21 | -- |
Total Paid Out | HKD0.602 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.61 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.38 | |
Div. Directional Score | 9.67 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
1268.HK | Ex Dividend Knight | 2023-09-20 | Semi-Annually | 0 | 0.00% | |
0322.HK | Ex Dividend Junior | 2023-06-07 | Annually | 0 | 0.00% | |
6049.HK | Ex Dividend Knight | 2023-06-08 | Annually | 0 | 0.00% | |
1820.HK | Ex Dividend Junior | 2023-10-20 | Semi-Annually | 0 | 0.00% | |
0855.HK | Ex Dividend Knight | 2023-09-19 | Semi-Annually | 0 | 0.00% | |
0006.HK | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
2600.HK | Ex Dividend Junior | 2023-06-23 | Sporadic | 0 | 0.00% | |
1385.HK | Ex Dividend Junior | 2023-06-27 | Sporadic | 0 | 0.00% | |
0458.HK | Ex Dividend Junior | 2023-09-07 | Sporadic | 0 | 0.00% | |
6826.HK | Ex Dividend Knight | 2023-07-04 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.161 | 1.500 | 6.77 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0973 | 1.200 | 6.76 | 8.11 | [0 - 0.3] |
returnOnEquityTTM | 0.148 | 1.500 | 9.47 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.145 | -1.000 | 8.55 | -8.55 | [0 - 1] |
currentRatioTTM | 1.536 | 0.800 | 7.32 | 5.86 | [1 - 3] |
quickRatioTTM | 1.425 | 0.800 | 6.32 | 5.06 | [0.8 - 2.5] |
cashRatioTTM | 0.633 | 1.500 | 7.59 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0968 | -1.500 | 8.39 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 21.84 | 1.000 | 3.02 | 3.02 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.588 | 2.00 | 9.80 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.363 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.142 | -1.500 | 9.43 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.902 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.185 | 1.000 | 8.29 | 8.29 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.220 | 1.000 | 4.33 | 4.33 | [0.2 - 2] |
assetTurnoverTTM | 0.604 | 0.800 | 9.31 | 7.45 | [0.5 - 2] |
Total Score | 12.97 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 4.74 | 1.000 | 9.62 | 0 | [1 - 100] |
returnOnEquityTTM | 0.148 | 2.50 | 9.66 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.363 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.04 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.588 | 2.00 | 9.80 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.145 | 1.500 | 8.55 | -8.55 | [0 - 1] |
pegRatioTTM | 0.158 | 1.500 | -2.28 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.196 | 1.000 | 7.61 | 0 | [0.1 - 0.5] |
Total Score | 6.38 |
Essex Bio-Technology Ltd
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej